Theocharopoulos, C.; Machairas, N.; Ziogas, I.A.; Mungo, B.; Del Chiaro, M.; Glatzounis, G.K.; Schulick, R.; Sotiropoulos, G.C.
Personalizing Treatment for Pancreatic Ductal Adenocarcinoma: The Emerging Role of Minimal Residual Disease in Perioperative Decision-Making. Cancers 2026, 18, 94.
https://doi.org/10.3390/cancers18010094
AMA Style
Theocharopoulos C, Machairas N, Ziogas IA, Mungo B, Del Chiaro M, Glatzounis GK, Schulick R, Sotiropoulos GC.
Personalizing Treatment for Pancreatic Ductal Adenocarcinoma: The Emerging Role of Minimal Residual Disease in Perioperative Decision-Making. Cancers. 2026; 18(1):94.
https://doi.org/10.3390/cancers18010094
Chicago/Turabian Style
Theocharopoulos, Charalampos, Nikolaos Machairas, Ioannis A. Ziogas, Benedetto Mungo, Marco Del Chiaro, Georgios K. Glatzounis, Richard Schulick, and Georgios C. Sotiropoulos.
2026. "Personalizing Treatment for Pancreatic Ductal Adenocarcinoma: The Emerging Role of Minimal Residual Disease in Perioperative Decision-Making" Cancers 18, no. 1: 94.
https://doi.org/10.3390/cancers18010094
APA Style
Theocharopoulos, C., Machairas, N., Ziogas, I. A., Mungo, B., Del Chiaro, M., Glatzounis, G. K., Schulick, R., & Sotiropoulos, G. C.
(2026). Personalizing Treatment for Pancreatic Ductal Adenocarcinoma: The Emerging Role of Minimal Residual Disease in Perioperative Decision-Making. Cancers, 18(1), 94.
https://doi.org/10.3390/cancers18010094
